Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting PI3K Signaling in Combination Cancer Therapy.

Trends in cancer - 1 Jun 2017

Pons-Tostivint Elvire, Thibault Benoît, Guillermet-Guibert Julie

Abstract excerpt

Targeting upstream phosphatidylinositol-3-kinases (PI3Ks) in the PI3K/Akt/mTOR pathway appears to be a promising therapy in solid cancers; however, first early clinical trials with PI3K inhibitors in monotherapy have been disappointing. A massive array of preclinical and clinical trials are currently evaluating combinations of PI3K inhibitors in targeted therapies. These combinations include co-treatments with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Molecular Targeted Therapy

Share to Phosphatidylinositol 3-Kinases

Share to Proto-Oncogene Proteins c-akt

Share to Synthetic Lethal Mutations

Share to TOR Serine-Threonine Kinases

Source

Identifiers

PMID: 28718419
DOI: 10.1016/j.trecan.2017.04.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting PI3K Signaling in Combination Cancer Therapy.PMID 28718419Read ↗

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read ↗

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read ↗

New phosphatidylinositol 3-kinase inhibitors for cancer.Semantic proximity Read ↗

Genomic Determinants of PI3K Pathway Inhibitor Response in CancerSemantic proximity Read ↗

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.Semantic proximity Read ↗

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read ↗

Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerationsSemantic proximity Read ↗

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read ↗

Cancer Therapies: Cellular and Molecular MechanismsSemantic proximity Read ↗

PI3K inhibitors for cancer treatment: where do we stand?Semantic proximity Read ↗

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects.Semantic proximity Read ↗

Targeting PI3K in Cancer: Any Good News?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.